File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis

TitleEfficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis
Authors
Keywords5-fluorouracil
Adjuvant chemotherapy
Capecitabine
Colorectal cancer
XELOX
Issue Date2013
PublisherAsian Pacific Organization for Cancer Prevention. The Journal's web site is located at http://www.apocpcontrol.org/
Citation
Asian Pacific Journal of Cancer Prevention, 2013, v. 14, n. 11, p. 6585-6590 How to Cite?
AbstractBackground: Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal. Moreover, uncertainties persist as to whether pharmacogenetic differences in Asian populations preclude equally tolerable and effective administration of these drugs. Method: One hundred consecutive patients with resected colorectal cancer received adjuvant XELOX (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 900 mg/m2 twice daily on day 1 to 14 every 3 weeks for 8 cycles) at Queen Mary Hospital, Hong Kong. Endpoints monitored during follow-up were disease-free survival (DFS) and disease recurrence, overall survival (OS) and adverse events (AEs). Results: The median patient age was 56 years, 56% were diagnosed with rectal cancer and 44% with colonic cancer. After a median follow-up of 4.3 years (95% confidence interval, 3.2-4.7), 24 recurrences were confirmed including 13 patients who died due to progressive disease. Four-year DFS was 81% in colon cancer patients and 67% in rectal cancer patients (p=0.06 by log-rank test). For the cohort as a whole, OS was 90% at 3 years and 84% at 5 years. Treatment-related AEs led to early withdrawal in four patients. The commonest non-hematological AEs were neuropathy (91%), hand-foot syndrome (49%) and diarrhea (46%), while the commonest grade 3/4 AEs were neutropenia (11%) and diarrhea (10%). Conclusion: These results confirm the favourable long term survival benefit with good tolerability in using adjuvant XELOX in treating East Asian colorectal cancer patients.
Persistent Identifierhttp://hdl.handle.net/10722/199937
ISSN
2014 Impact Factor: 2.514
2015 SCImago Journal Rankings: 0.813
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChiu, Joanne-
dc.contributor.authorTang, Vikki-
dc.contributor.authorLeung, Roland-
dc.contributor.authorWong, Hilda-
dc.contributor.authorChu, Kinwah-
dc.contributor.authorPoon, Jensen-
dc.contributor.authorEpstein, Richard John-
dc.contributor.authorYau, Thomas-
dc.date.accessioned2014-07-26T23:10:56Z-
dc.date.available2014-07-26T23:10:56Z-
dc.date.issued2013-
dc.identifier.citationAsian Pacific Journal of Cancer Prevention, 2013, v. 14, n. 11, p. 6585-6590-
dc.identifier.issn1513-7368-
dc.identifier.urihttp://hdl.handle.net/10722/199937-
dc.description.abstractBackground: Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal. Moreover, uncertainties persist as to whether pharmacogenetic differences in Asian populations preclude equally tolerable and effective administration of these drugs. Method: One hundred consecutive patients with resected colorectal cancer received adjuvant XELOX (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 900 mg/m2 twice daily on day 1 to 14 every 3 weeks for 8 cycles) at Queen Mary Hospital, Hong Kong. Endpoints monitored during follow-up were disease-free survival (DFS) and disease recurrence, overall survival (OS) and adverse events (AEs). Results: The median patient age was 56 years, 56% were diagnosed with rectal cancer and 44% with colonic cancer. After a median follow-up of 4.3 years (95% confidence interval, 3.2-4.7), 24 recurrences were confirmed including 13 patients who died due to progressive disease. Four-year DFS was 81% in colon cancer patients and 67% in rectal cancer patients (p=0.06 by log-rank test). For the cohort as a whole, OS was 90% at 3 years and 84% at 5 years. Treatment-related AEs led to early withdrawal in four patients. The commonest non-hematological AEs were neuropathy (91%), hand-foot syndrome (49%) and diarrhea (46%), while the commonest grade 3/4 AEs were neutropenia (11%) and diarrhea (10%). Conclusion: These results confirm the favourable long term survival benefit with good tolerability in using adjuvant XELOX in treating East Asian colorectal cancer patients.-
dc.languageeng-
dc.publisherAsian Pacific Organization for Cancer Prevention. The Journal's web site is located at http://www.apocpcontrol.org/-
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention-
dc.subject5-fluorouracil-
dc.subjectAdjuvant chemotherapy-
dc.subjectCapecitabine-
dc.subjectColorectal cancer-
dc.subjectXELOX-
dc.titleEfficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.7314/APJCP.2013.14.11.6585-
dc.identifier.pmid24377572-
dc.identifier.scopuseid_2-s2.0-84892451418-
dc.identifier.hkuros236996-
dc.identifier.hkuros248098-
dc.identifier.hkuros248104-
dc.identifier.volume14-
dc.identifier.issue11-
dc.identifier.spage6585-
dc.identifier.epage6590-
dc.identifier.isiWOS:000329829200068-
dc.publisher.placeKorea-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats